NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly created shares were payable to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences announced that its board has approved a stock buyback plan on Thursday, December 7th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

Edwards Lifesciences Corp (NYSE:EW) released its earnings results on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.11 by $0.11. The medical research company had revenue of $938 million for the quarter, compared to analysts' expectations of $936.69 million. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.94 earnings per share. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

18 brokerages have issued twelve-month price targets for Edwards Lifesciences' shares. Their forecasts range from $115.00 to $180.00. On average, they expect Edwards Lifesciences' share price to reach $149.3333 in the next year. View Analyst Ratings for Edwards Lifesciences.

Edwards Lifesciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 5,610,181 shares, an increase of 62.3% from the April 30th total of 3,456,057 shares. Based on an average daily trading volume, of 1,266,171 shares, the short-interest ratio is currently 4.4 days. Currently, 2.7% of the shares of the stock are short sold.

Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Halyard Health (HYH), Wright Medical Group (WMGI), Invacare (IVC), Consort Medical (CSRMY), Sientra (SIEN) and RTI Surgical (RTIX).

News articles about EW stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.13 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 45.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Edwards Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.43%), American Century Companies Inc. (1.32%), Northern Trust Corp (1.13%), Wells Fargo & Company MN (1.06%), Disciplined Growth Investors Inc. MN (0.98%) and Massachusetts Financial Services Co. MA (0.97%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., WCM Investment Management CA, Sei Investments Co., Blair William & Co. IL, DekaBank Deutsche Girozentrale, Envestnet Asset Management Inc., Schroder Investment Management Group and Swiss National Bank. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., BlackRock Inc., OppenheimerFunds Inc., Rockefeller Capital Management L.P., Royal Bank of Canada, Chicago Capital LLC, Prudential Financial Inc. and Country Trust Bank. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $153.60.

Edwards Lifesciences has a market capitalization of $32.15 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]